Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
15
×
national blog main
biotech
boston blog main
clinical trials
boston top stories
fda
indiana blog main
indiana top stories
national top stories
eli lilly
san francisco blog main
san francisco top stories
boston
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
amgen
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
san diego blog main
san diego top stories
seattle blog main
seattle top stories
teva pharmaceutical
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
europe blog main
europe top stories
avapritinib
blueprint medicines
calcitonin gene-related peptide
cancer
chronic migraine
What
approval
15
×
drug
fda
won
new
developed
medicine
medicines
migraine
therapy
blueprint
cancer
class
eli
lilly
nod
second
therapeutics
amgen
announced
approved
bio
carries
companies
decades
friday
gene
late
marketing
oral
pain
ret
rna
roche
roundup
seek
starts
treat
type
wins
Language
unset
Current search:
approval
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines